Macrovascular complication phenotypes in type 2 diabetic patients

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Papa, Giuseppe ^a   Degano, Claudia ^a   Iurato, Maria P ^a   Licciardello, Carmelo ^a   Maiorana, Raffaella ^a   Finocchiaro, Concetta ^a  

^a Centro Catanese di Medicina e Chirurgia Clinic   (Italy)

Author keywords

Cardiovascular risk factors; Macrovascular disease; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIOGRAPHY; ARTICLE; CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETIC MICROANGIOPATHY; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; OXYGEN TENSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; RETROSPECTIVE STUDY;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; VASCULAR DISEASES;

EID: 84872294342     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-20     Document Type: Article

References (29)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1999, 339:229-234.
2. Brun E, Nelson NG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al. Verona Diabetes Study. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000, 23:1119-1123. 10.2337/diacare.23.8.1119, 10937508.
3. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31(3):596-615. American Diabetes Association.
4. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
6. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001, 44(Suppl. 2):S14-S21.
7. Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S, Makriyiannis D, Tsatsoulis A, Michalis LK. Determinants of vascular function in patients with type 2 diabetes. Cardiovasc Diabetol 2012, 11:127. 10.1186/1475-2840-11-127, 3490819, 23062182.
8. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, patophysiology, and management. JAMA 2002, 287:2570-2581. 10.1001/jama.287.19.2570, 12020339.
9. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980, 69:498-506. 10.1016/S0149-2918(05)80002-5, 7424939.
10. Conrad MC. Large and small artery occlusion in diabetics and nondiabetics with severe vascular disease. Circulation 1967, 36:83-91. 10.1161/01.CIR.36.1.83, 6027218.
11. Gragnoli C. Proteasome modulator 9 and macrovascular pathology of T2D. Cardiovasc Diabetol 2011, 10:32. 10.1186/1475-2840-10-32, 3102609, 21496327.
12. Reynoso-Noveron N, Mehta R, Almeda-Valdes P, Rojas-Martinez R, Villalpando S, Hernandez-Avila M, Aquilar-Salinas CA. Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey. Cardiovasc Diabetol 2011, 10:1. 10.1186/1475-2840-10-1, 3023678, 21214916.
13. Sousa AG, Selvatici L, Krieger JE, Pereira AC. Association between genetics of diabetes, coronary artery disease, and macrovascular complications: exploring a common ground hypothesis. Rev Diabet Stud 2011, 8(2):230-244. 10.1900/RDS.2011.8.230, 3280008, 22189546.
14. Jermendy G, Horvath T, Littvay L, Steinbach R, Jermendy AL, Tarnoki AD, Tarnoki DL, Metneki J, Osztovits J. Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study. Cardiovasc Diabetol 2011, 10:96. 10.1186/1475-2840-10-96, 3219730, 22050728.
15. Milicevic Z, Raz I, Beattie BD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural History of Cardiovascular Disease in Pazients with diabetes. Diabetes Care 2008, 31(2):S155-S160. 10.2337/dc08-s240, 18227478.
16. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000, 23:1830-1934. 10.2337/diacare.23.12.1830, 11128361.
17. Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, Finer N, Sharma AM, Maggiori AP, Torp-Pedersen C. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 2012, 55(9):2348-2355. 10.1007/s00125-012-2584-3, 22638548.
18. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group.
19. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, , et al. ADVANCE Collaborative Group Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572. ADVANCE Collaborative Group.
20. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431, 19092145.
21. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009, 23(9677):1765-1772.
22. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
23. Reddy MA, Natarajan R. Role of epigenetic mechanisms in the vascular complications of diabetes. Subcell Biochem 2012, 61:435-454. 10.1007/978-94-007-4525-4_19, 23150262.
24. Gurfinkel R, Joy TR. Anacetrapib: hope for CETP inhibitors?. Cardiovasc Ther 2011, 29(5):327-339. 10.1111/j.1755-5922.2010.00142.x, 20406242.
25. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306(19):2099-2109. 10.1001/jama.2011.1649, 22089718.
26. Verhagen SN, Wassinik AM, Van Der Graaf Y, Gorter PM, Visseren FL, SMART Study Group Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without know diabetes. The SMART study. Cardiovasc Diabetol 2011, 10:100. 10.1186/1475-2840-10-100, 3268731, 22098712, SMART Study Group.
27. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabet Med 2004, 21:52-58. 10.1046/j.1464-5491.2003.01068.x, 14706054.
28. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214. 10.2337/diabetes.52.5.1210, 12716754.
29. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complication Study. Diabetes Care 2002, 25:1135-1141. 10.2337/diacare.25.7.1135, 12087010.